Sort
15,273 grants matching “antimicrobial resistance”
Anti-biofilm agents for the treatment of pulmonary infection in cystic fibrosis p
$826,326David Jung · Agile Sciences, Inc. · R42 · FY2015 · AI
Epithelial biology: morphogenesis and damage signaling
$826,172David Bilder · University Of California Berkeley · R35 · FY2025 · GM
HTS for copper-activated inhibitors against MRSA
$826,146Frank Wolschendorf · University Of Alabama At Birmingham · R01 · FY2016 · AI
Trial to Reduce Antimicrobial Use in Nursing home residents with Alzheimer's disease and other Dementias (TRAIN-AD)
$826,001Susan L Mitchell · Hebrew Rehabilitation Center For Aged · R37 · FY2019 · AG
Chemically modified minocycline for treatment of alcohol use disorder
$824,590Susan E. Bergeson · Texas Tech University Health Scis Center · U01 · FY2018 · AA
Programmable benchtop bioreactors for scalable eco-evolutionary dynamics of the human microbiome
$823,196Ahmad Samir Khalil · Boston University (Charles River Campus) · R01 · FY2024 · AI
Genes/Pathways for ATG Gene-dependent Inhibition of Viruses & Parasite Infection
$822,472Herbert W Virgin · Washington University · U19 · FY2015 · AI
Host-pathogen interactions during hospital adaptation of MRSA
$821,192Bo Shopsin · New York University School Of Medicine · R01 · FY2021 · AI
Antimicrobial catheters with cell and tissue compatibility
$820,970Kennard M Brunson · Wynnvision, Llc · R44 · FY2017 · DK
Rapid, Cost-Effective Nucleic Acid Testing for Active Surveillance and Molecular
$820,894Ben Hindson · Quantalife, Inc. · R01 · FY2010 · EB
A method for the culture-free discovery and host affiliation of novel viruses from metagenomic samples
$820,379Ivan Liachko · Phase Genomics, Inc. · R44 · FY2022 · AI
A method for the culture-free discovery and host affiliation of novel viruses from metagenomic samples
$820,379Ivan Liachko · Phase Genomics, Inc. · R44 · FY2021 · AI
Targeted Clinical Trials to Reduce the Risk of Antimicrobial Resistance
$820,333Alehandro Hoberman · University Of Pittsburgh At Pittsburgh · N01 · FY2013 · AI
Targeted Clinical Research Program to Address Selected Viral Infections
$819,823Richard Whitley · University Of Alabama At Birmingham · N01 · FY2015 · AI
New Tricks for 'Old' Drugs: PK/PD of Polymyxin Nonantibiotic Combinations
$819,605Jian Li · Monash University · R01 · FY2018 · AI
THE EXTRAORDINARY CONNECTIONS BETWEEN FLAVONOL AND BENZOATE METABOLISM
$818,368Gilles J Basset · University Of Florida · · FY2022 · BIO
Use of De Novo Synthesis Approaches and Structure-guided Design to Optimize Therapeutic Properties of Streptothricin Class Antimicrobials
$818,324James E Kirby · Beth Israel Deaconess Medical Center · R01 · FY2020 · AI
Pro-apoptotic Drugs as Host-Directed Treatments for Pulmonary Tuberculosis
$817,941Sanjay Jain · Johns Hopkins University · R56 · FY2024 · AI
Non-Modulation Phenotype and Vascular Dysfunction in Diabetes Mellitus
$817,696Gordon H Williams · Brigham And Women'S Hospital · R01 · FY2007 · HL
A prospective trial of oral azithromycin when added to inhaled tobramycin in CF
$817,198David Paul Nichols · National Jewish Health · R01 · FY2015 · HL
Vaccine and Treatment Evaluation Units: Noninferiority Trial to Inform Treatment of Lower Respiratory Tract Infections (LRTI)
$816,972Emmanuel B Walter · Duke University · N01 · FY2019 · AI
Rapid, Breath Volatile Metabolite-Based Diagnosis, Species Identification, and Antibiotic Resistance Profiling in Bacterial Pneumonia
$816,494Sophia Koo · Brigham And Women'S Hospital · R01 · FY2024 · AI
Structure-based microbially targeted prodrugs
$816,384Audrey Ragan Odom John · Children'S Hosp Of Philadelphia · R01 · FY2023 · AI
Targeting Estrogenic pathways in Tregs to promote ARDS resolution
$816,322Franco Rafael D'alessio · Johns Hopkins University · R01 · FY2022 · HL
Measuring Intralesional Drug Exposures in Cavitary TB using Noninvasive In Vivo PET Imaging
$816,236Sanjay Jain · Johns Hopkins University · R01 · FY2020 · AI